Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S

NCT: NCT06540079 · COMPLETED

NCT IDNCT06540079
StatusCOMPLETED
Start Date2024-12-18
Completion2026-06-17
SponsorBiotronik, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia CSP S pacing lead when implanted in the left bundle branch area (LBBA). Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will be assessed by evaluating implant success rate.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑